BR9914066A - Human complement c3-degrading polypeptide from streptococcus pneumoniae - Google Patents

Human complement c3-degrading polypeptide from streptococcus pneumoniae

Info

Publication number
BR9914066A
BR9914066A BR9914066-7A BR9914066A BR9914066A BR 9914066 A BR9914066 A BR 9914066A BR 9914066 A BR9914066 A BR 9914066A BR 9914066 A BR9914066 A BR 9914066A
Authority
BR
Brazil
Prior art keywords
human complement
streptococcus pneumoniae
degrading polypeptide
polypeptides
polypeptide
Prior art date
Application number
BR9914066-7A
Other languages
Portuguese (pt)
Inventor
Margaret K Hostetter
David J Finkel
Qi Cheng
Bruce A Green
Amy W Masi
Original Assignee
Univ Minnesota
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, American Cyanamid Co filed Critical Univ Minnesota
Publication of BR9914066A publication Critical patent/BR9914066A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"POLIPEPTìDIO DEGRADADOR DE C3 DE COMPLEMENTO HUMANO DE STREPTOCOCCUS PNEUMONIAE". A presente invenção refere-se à identificação e uso de uma família de polipeptídios degradando complemento humano C3, expressos por S. pneumoniae. Os polipeptídios tem pesos moleculares de cerca de 15 kD a cerca de 20 kD ou cerca de 75 kDa a cerca de 95 kDa, por exemplo. Os polipeptídios preferidos desta invenção incluem as seq³ências de aminoácido de SEQ ID N<0>: 2 e SEQ ID N<0>: 5."HUMAN COMPLEMENT C3 POLYPEPTIDE DEGRADATOR OF STREPTOCOCCUS PNEUMONIAE". The present invention relates to the identification and use of a family of polypeptides degrading human complement C3, expressed by S. pneumoniae. Polypeptides have molecular weights of about 15 kD to about 20 kD or about 75 kDa to about 95 kDa, for example. Preferred polypeptides of this invention include the amino acid sequences of SEQ ID N <0>: 2 and SEQ ID N <0>: 5.

BR9914066-7A 1998-09-24 1999-09-24 Human complement c3-degrading polypeptide from streptococcus pneumoniae BR9914066A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10173698P 1998-09-24 1998-09-24
US28309499A 1999-03-31 1999-03-31
PCT/US1999/022362 WO2000017370A1 (en) 1998-09-24 1999-09-24 HUMAN COMPLEMENT C3-DEGRADING POLYPEPTIDE FROM $i(STREPTOCOCCUS PNEUMONIAE)

Publications (1)

Publication Number Publication Date
BR9914066A true BR9914066A (en) 2002-04-23

Family

ID=26798575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914066-7A BR9914066A (en) 1998-09-24 1999-09-24 Human complement c3-degrading polypeptide from streptococcus pneumoniae

Country Status (10)

Country Link
EP (1) EP1115875A1 (en)
JP (1) JP2002526082A (en)
KR (1) KR20010089280A (en)
CN (1) CN1352691A (en)
AU (1) AU6060899A (en)
BR (1) BR9914066A (en)
CA (1) CA2343931A1 (en)
IL (1) IL142017A0 (en)
MX (1) MXPA01003073A (en)
WO (1) WO2000017370A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737125T3 (en) * 1996-10-31 2015-02-26 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
ATE422899T1 (en) 1998-12-21 2009-03-15 Medimmune Inc STREPTOCOCCUS PNEUMONIAE PROTEINS AND IMMUNOGENIC FRAGMENTS FOR VACCINES
EP1950302B1 (en) 1998-12-23 2012-12-05 ID Biomedical Corporation of Quebec Streptococcus antigens
TR200200633T2 (en) * 1998-12-23 2002-06-21 Shire Biochem Inc. New streptococcus antigens
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
CA2413450C (en) * 2000-06-20 2014-02-18 Shire Biochem Inc. Streptococcus antigens
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
JP4768620B2 (en) * 2003-05-15 2011-09-07 ジェネンテック， インコーポレイテッド Methods and compositions for the prevention and treatment of sepsis
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc Multivalent pneumococcal polysacharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007047995A2 (en) * 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
WO2009000825A2 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
EA201001479A1 (en) 2008-04-16 2011-06-30 Глаксосмитклайн Байолоджикалс С.А. VACCINE
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2012156391A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
DE69737125T3 (en) * 1996-10-31 2015-02-26 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
CN1253589A (en) * 1997-04-24 2000-05-17 美国明尼苏达州大学 Human complement C3-degrading proteinase from streptococcus pneumoniae
CN1291233A (en) * 1997-09-24 2001-04-11 美国明尼苏达州大学 Human complement (3-degrading proteinase from i (streptococcus pheumoniae)

Also Published As

Publication number Publication date
CA2343931A1 (en) 2000-03-30
JP2002526082A (en) 2002-08-20
CN1352691A (en) 2002-06-05
MXPA01003073A (en) 2002-04-24
KR20010089280A (en) 2001-09-29
AU6060899A (en) 2000-04-10
IL142017A0 (en) 2002-03-10
EP1115875A1 (en) 2001-07-18
WO2000017370A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
BR9914066A (en) Human complement c3-degrading polypeptide from streptococcus pneumoniae
BR9812525A (en) Human complement degrading proteinase c3 from streptococcus pneumoniae
EP1484339A3 (en) Kallikrein-inhibiting &#34;Kunitz Domain&#34; proteins and nucleic acids encoding the same
PT751957E (en) PEPTIDIC FRAGMENTS OF STRESS MICROBIAL PROTEINS AND PHARMACEUTICAL COMPOSITION BASED ON THESE FRAGMENTS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
EP0378641A4 (en) Novel antimicrobial peptide, compositions containing same and uses thereof
SE8901687D0 (en) FIBRONECTIN BINDING PROTEIN AS WELL AS IT&#39;S PREPARATION
BR9609399A (en) Elements of streptococcal heat shock proteins of the hsp70 family
DE69838143D1 (en) ANTIMICROBIAL PEPTIDES
WO1998004702A3 (en) Proteins, in particular membrane proteins, of helicobacter pylori, their preparation and use
ATE462006T1 (en) ISOFORM OF VEGF
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
DE69533255D1 (en) ISOLATED p27 PROTEIN AND NUCLEIC ACID CODING THEREOF
CA2105057A1 (en) Dna sequences which code for virulence characteristics of streptococcus suis and part thereof polypeptides and antibodies derived therefrom and the use thereof for the diagnosis of and protection against infection by s. suis in mammals, including man
MXPA03005386A (en) Recombinant protective protein from $i(streptococcus pneumoniae).
BR9510067A (en) Peptide capable of interacting with the sh3 domain of the antibody gap protein or antibody fragment directed against a polypeptide nucleotide sequence encoding an antisense nucleic acid polypeptide capable of at least partially inhibiting the production of polypeptides its use pharmaceutical composition and use of an antibody or antibody fragment
AU3850997A (en) Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines
SE9003374D0 (en) A COLLAGEN BINDING PROTEIN AS WELL AS IT&#39;S PREPARATION
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
WO2007066018A3 (en) Novel peptides and the biological use thereof
PT938329E (en) IMMUNOGENIC TLP COMPOSITION
DE60234843D1 (en) MODIFIED PEPTIDES AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
BR9809405A (en) Streptococcus pneumoniae proteinase that degrades human complement c3
DE60036676D1 (en) G-PROTEIN-COUPLED RECEPTOR-SIMILAR PROTEINS
WO2001098355A3 (en) Cgi-69 compositions and methods of use
WO2004042043A3 (en) Crystal structures of bacterial ribulose-phosphate 3-epimerases

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]